China Biologic Products Announces Record Third Quarter 2010 Results

- Q3 revenue grew 33.2% to $36.0 million

- Non-GAAP adjusted net income grew 48.7% to $10.5 million

PR Newswire
TAI'AN, China
Nov 16, 2010

TAI'AN, China, Nov. 16, 2010 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO) ("China Biologic" or the "Company"), one of the leading plasma-based biopharmaceutical companies in the People's Republic of China ("PRC"), operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. ("Shandong Taibang") and Guiyang Dalin Biologic Technologies Co., Ltd. ("Dalin"), and its equity investment in Xi'an Huitian Blood Products Co., Ltd. ("Huitian"), today reported financial results for the third quarter ended September 30, 2010.

Third Quarter 2010 Highlights

    --  Revenues increased 33.2% period-over-period to $36.0 million
    --  Gross profit rose 36.1% period-over-period to $27.3 million,
        representing a gross margin of 75.9%, as compared to 74.3% a year ago
    --  Income from operations grew 34.2% to $18.8 million
    --  GAAP net income attributable to controlling interest was $13.7 million,
        or $0. 53 per diluted share, including a $3.8 million non-cash gain from
        change in the fair value of derivative liabilities
    --  Excluding the non-cash gain from change in fair value of derivative
        liabilities, interest on convertible notes and non-cash employee
        compensation, non-GAAP adjusted net income was $10.5 million or $0.39
        per diluted share, a 48.7% increase from $7.1 million, or $0.33 per
        diluted share a year ago
    --  The Company established Ning Yang Taibang Plasma Company and Yi Shui
        Taibang Plasma Company in July 2010 for the purpose of operating two new
        plasma stations in Shandong Province, PRC

"Our 2010 third quarter results were very strong, with 33.2% growth in revenues and 48.7% growth in adjusted net income, driven by robust demand and an overall favorable pricing environment for our plasma-based products," said Mr. Chao Ming Zhao, Chief Executive Officer of China Biologic. "During the quarter, we established two new plasma collection stations in Yishui and Ninyang counties in Shandong Province, and we expect to begin trial collections at the Yishui station by the end of the year and at the Ninyang station by early 2011. We expect that when these sites are at their full capacity, we will realize up to 80 metric tons of incremental plasma collection capacity."

Third Quarter 2010 Results

Revenue for the third quarter of 2010 increased 33.2% to $36.0 million, from $27.0 million in the same period of 2009. Revenue growth was primarily attributable to price increases ranging from 6.2% to 55.8% across the Company's approved product categories, with the exception of human albumin products and human immunoglobulin products, which registered price declines of 4.3% and 11.8%, respectively. Pricing of human albumin products decreased period-over-period due to higher industry supply primarily from imports. Nonetheless, strong volume growth led to a 51.3% period-over-period increase in human albumin revenue to $17.5 million, or 48.6% of total sales, making it the Company's largest revenue contributor.

Human Immunoglobulin for Intravenous Injection, the Company's second largest revenue contributor at 36.3% of total sales, experienced average period-over-period price increases of 27.0% in third quarter 2010. Human Hepatitis B Immunoglobulin experienced the sharpest average price increase among the Company's product categories, up 55.8%, compared to the prior year period, and contributed 7.1% of total revenues in third quarter 2010. The average price for human tetanus immunoglobulin products, which contributed 4.1% of total revenues, increased 6.2% period-over-period. The average price for human rabies immunoglobulin products, which contributed 2.9% of total revenues, increased 51.4% period-over-period. The average price for human immunoglobulin products, which contributed 0.5% of total revenues, decreased 11.8%, as compared to the same period in 2009.

Gross profit for the third quarter of 2010 was $27.3 million, up 36.1% from $20.1 million in the third quarter of 2009. Gross profit margin expanded to 75.9%, from 74.3% in the same period a year ago. The gross margin expansion was primarily attributable to increases in the average selling price of four of the Company's six top product categories.

Operating expenses in the third quarter increased 40.4% to $8.5 million, from $6.1 million in the same period last year. Higher expenses primarily reflected a 64.6% increase in research and development spending, mostly related to development of two late stage pipeline products for which the Company expects to receive State Food and Drug Administration ("SFDA") approval in early 2011. Selling expenses increased 259.9% period-over-period to $2.2 million due to intensified promotional and conference activities as the Company continues its efforts in expanding its reach into hospital and inoculation centers. General and administrative expenses increased 12.8% period-over-period in the third quarter of 2010 to $5.8 million, or 16.2% of total sales, versus $5.2 million, or 19.1% of total sales for the same period in 2009.

Income from operations in the 2010 third quarter was $18.8 million, a 34.2% increase from $14.0 million during the same period a year ago. Operating margin rose to 52.3%, from 51.9% in the same period last year.

Total other income was $3.5 million in the 2010 third quarter, as compared to net other expense of $14.3 million in the same period last year. For the three months ended September 30, 2010 and 2009, the Company recognized an income from the change in the fair value of warrant liabilities in the amount of $3.8 million and a loss of $13.2 million, respectively.

Income taxes increased to $3.5 million in the 2010 third quarter, from $2.5 million in the prior year. Net income attributable to controlling interest for the 2010 third quarter was $13.7 million, or $0.53 per diluted share, as compared to $(6.2) million, or $(0.29) per diluted share, during the 2009 third quarter.

Excluding non-cash employee compensation expenses, change in the fair value of derivative liabilities and interest related to the convertible notes under the if-converted method, non-GAAP adjusted net income for the three months ended September 30, 2010 was $10.5 million, or $0.39 per diluted share, up 48.7% from $7.1 million, or $0.33 per diluted share, in the same 2009 period.

Nine Months Results

For the first nine months of 2010, total revenue was $104.0 million, up 27.8% from the first nine months of 2009. Gross profit for the first nine months of 2010 was $77.9 million, up 31.9% from $59.0 million in the comparable period a year ago. Gross margin for the first nine months of 2010 was 74.9%, as compared to 72.5% for the same period in 2009. The increase in gross margin was due mainly to increased selling prices, ranging from 15.1% to 213.6%, across all of the Company's products, except for human albumin products, which decreased by 0.6%. Income from operations for the period was $54.8 million, up 35.0% from $40.6 million in the first nine months of 2009. Net income attributable to controlling interest for the first nine months of 2010 was $37.2 million, up 637.9% from $5.0 million in the first nine months of 2009. Fully diluted earnings per share were $1.44 for the first nine months of 2010, compared to $0.23 in the first nine months of 2009. Excluding non-cash employee compensation expenses, change in the fair value of derivative liabilities and interest related to the convertible notes under the if-converted method, non-GAAP adjusted net income for the nine months ended September 30, 2010 was $28.9 million, or $1.09 per diluted share, an increase of 44.5% from non-GAAP net income of $20.0 million, or $0.92 per fully diluted share, for the nine months ended September 30, 2009.

Financial Condition

As of September 30, 2010, the Company had $64.6 million in cash and cash equivalents, approximately $75.3 million in working capital, and a current ratio of 2.6. Total stockholders' equity at the end of the quarter was $93.8 million, up 89.7% from $49.5 million at the end of 2009.

The Company generated $31.3 million in net cash from operating activities during the first nine months of 2010, as compared to $35.5 million in the same period of 2009, which included a $4.2 million advanced receipt from customers.

The increase in cash outflow for inventory during the first nine months of 2010, compared to the same period last year, is a direct result of the implementation of the 90-day quarantine period by the PRC government, which caused a longer staging period for its raw material plasma inventory. During the first nine months of 2010, as the Company increased its sales directly to end-users, hospitals and inoculation centers, it also experienced a slower turn-over of its accounts receivable compared to the same period last year.

Net cash used in investing activities for the nine months ended September 30, 2010 was $11.6 million, as compared to $6.1 million in the same period of 2009. During the first nine months ended September 30, 2010, $1.5 million was used for the acquisition of Ziguang Bio-tech Company, $2.5 million for the final payment for the Dalin acquisition, $1.8 million for equipment for Shandong Taibang, and $5.8 million for the Company's plasma companies' buildings and construction in process in Dalin.

Net cash used in financing activities for the nine months ended September 30, 2010 totaled $10.2 million, as compared to $12.1 million provided by financing activities in the same period of 2009.

Recent Events and Updates

Acquisition of the 17.24% Minority Interest of Taibang Medical

On July 8, 2010, Logic China entered into an equity transfer agreement to purchase 100% of the equity interest in Taibang Medical from the Company's indirect majority-owned subsidiary Shandong Taibang, with a cash purchase price of RMB 6,440,000 (approximately $947,327). The equity transfer was registered with the local Administration for Industry and Commerce ("AIC") on September 10, 2010 and the purchase price was fully paid on September 23, 2010. With this equity transfer, Taibang Medical is now an indirect wholly-owned subsidiary of the Company and the Company will be able to consolidate its resources in the sales and marketing of Shandong Taibang and Qianfeng's products.

Distributions declaration by Shandong Taibang

On October 9, 2010, the board of directors of Shandong Taibang declared a RMB 70,000,000 (approximately $10,479,000) distribution to its 82.76% shareholder, Logic Express, the Company's wholly-owned subsidiary, and to its 17.24% shareholder, the Shandong Institute. The distribution to Logic Express was used to pay off the RMB 55,000,000 (approximately $8,233,500) loan due to Shandong Taibang, and the distribution to the Shandong Institute was made on October 25, 2010.

Redemption of Convertible Notes

On November 10, 2010, the remaining holder of the Company's convertible notes, issued in the Company's June 2009 financing, exercised its right to convert $2,800,000 payable under its note into an aggregate of 700,000 shares of the Company's common stock. As a result, only a convertible note in the principal amount of $4,700,000 remains outstanding as of November 16, 2010.

2010 Guidance and Business Outlook

China Biologic reaffirms its guidance for 2010 of revenues in the range of $142 million and $149 million and adjusted net income between $34 million and $36 million. Guidance for 2010 adjusted net income excludes any non-cash gain or loss related to change in the fair value of derivative liabilities, stock-based compensation expense and any adjustments in the U.S. federal income tax provision in 2010 related to the expiration of the look-through exception for Subpart F income on December 31, 2009, and excludes any acquisitions, new product approvals or operational impact from new plasma stations. The guidance also does not assume any material price or volume increases during the year.

Mr. Zhao added, "We believe that the results for the first nine months of 2010 reinforce the merits of China Biologic's strategy to acquire or build new locations, scale up our existing plasma infrastructure, and advance exciting products through our pipeline. From investing in strategic marketing to drive collection center donor volumes, to developing closer relationships with hospitals and inoculation centers, we intend to maximize the utilization of our growing plasma network. We expect that our strong balance sheet and solid operating cash flow will provide us with the resources to take advantage of opportunities created by rising consumer demand and tight supply conditions based on strict government regulation. On the research and development front, we continue to expect our applications for production of Human Prothrombin Complex Conentrate and Human Coagulation Factor VIII to be approved by the SFDA in early 2011. Heading into next year, we intend to leverage our expertise in the field to capitalize further on China's under-pentrated plasma market and build value for our shareholders."

Conference Call

China Biologic will host a conference call at 9:00 a.m. EST on Tuesday, November 16, 2010, to discuss the third quarter 2010 financial results. To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 877-409-5468. International callers should dial +1-702-894-2400. The pass code for the call is 23890623. A replay will be available for 14 days starting on Tuesday, November 16, 2010 at 11:00 a.m. EST. To access the replay, dial 800-642-1687, international callers should dial +1-706-645-9291. The conference pass code is 23890623.


              CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES

               RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
     FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2010, AND 2009


                                 Three Months          Three Months
                                     Ended                 Ended
                                 September 30,         September 30,
                                       2010                   2009
                                 -------------          -------------
                                 Net      Diluted       Net      Diluted
                               Income        EPS      Income        EPS
                              -------     --------   -------     --------
    Adjusted net income -
     non GAAP                10,489,724      $0.39   7,056,078      $0.33
    Non-cash employee
     compensation (1)            63,812      $0.00       7,314      $0.00
    Loss (income) in fair
     value of derivative
     liabilities (2)         (3,792,793)    $(0.14) 13,242,333      $0.61
    Net income attributable
     to controlling interest
     for diluted EPS (3)     14,218,705      $0.53  (6,193,569)    $(0.29)
    Interest add-back on
     convertible notes          543,814                      -
    Net income attributable
     to controlling interest 13,674,891             (6,193,569)
    Weighted average number
     of shares -diluted      26,578,471             21,632,793




                                  Nine Months           Nine Months
                                     Ended                 Ended
                                 September 30,         September 30,
                                       2010                    2009
                                 -------------           -------------
                                 Net      Diluted       Net      Diluted
                               Income        EPS      Income        EPS
                              -------     --------   -------     --------
    Adjusted net income -non
     GAAP                    28,942,653      $1.09  20,028,863      $0.92
    Non-cash employee
     compensation (1)           681,653      $0.03      62,281      $0.00
    Loss (income) in fair
     value of derivative
     liabilities (2)         (9,897,199)    $(0.37) 14,931,088      $0.69
    Net income attributable
     to controlling interest
     for diluted EPS (3)     38,158,199      $1.44   5,034,494      $0.23
    Interest add-back on
     convertible notes        1,000,125                      -
    Net income attributable
     to controlling interest 37,158,074              5,035,494
    Weighted average number
     of shares -diluted      26,575,801             21,767,086

    (1) Non-cash compensation expenses related to options granted to
    employees and directors under the Company's 2008 Equity Incentive
    Plan
    (2)Adoption of a new accounting rule effective January 1, 2009
    requires changes in the fair value of derivative liabilities to be
    recognized in earnings each quarter.
    (3)Net Income attributable to controlling interest for calculating
    diluted earnings per share includes interest add-back on
    Convertible Notes.

Use of Non-GAAP Financial Measures

This press release contains non-GAAP financial measures that exclude non-cash compensation expenses related to options granted to employees and directors under the Company's 2008 Equity Incentive Plan and changes in the fair value of derivative liabilities, including warrants and derivative instruments (including the conversion option) embedded in the Company's Senior Secured Convertible Notes. To supplement the Company's condensed consolidated financial statements presented on a GAAP basis, the Company has provided non-GAAP financial information excluding the impact of this item in this release. The Company's management believes that these non-GAAP measures provide investors with a better understanding of how the results relate to the Company's historical performance. A reconciliation of the adjustments to GAAP results appears in the table accompanying this press release. This additional non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP information provided by other companies.

About China Biologic Products, Inc.

China Biologic Products, Inc., through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently one of the leading plasma-based biopharmaceutical companies in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China. Please see the Company's website http://www.chinabiologic.com for additional information.

Safe Harbor Statement

This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiaries. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the ability of the Company to achieve the financial guidance provided by the management; the likelihood that customer demand will continue to rise and the continued ability of the Company to take advantage of opportunities created by such consumer demand and tight supply conditions based on strict government regulation; the ability of the Company to win SFDA approval for its research and development pipeline projects, and commercially launch new products;; the Company's ability to otherwise achieve its commercial objectives, including its ability to continue building new or expanding existing plasma collection stations to increase plasma collection capacity and maximizing the utilization of its growing plasma network, and to gain market share and further strengthen the Company's leadership in the PRC plasma market; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

-FINANCIAL TABLES FOLLOW -


                             CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES
                                       CONSOLIDATED BALANCE SHEETS
                             AS OF SEPTEMBER 30, 2010 and DECEMBER 31, 2009

                                ASSETS
                                ------
                                                  September         December
                                                          30,              31,
                                                         2010             2009
                                                         ----             ----
                                                 (Unaudited)
                                                 -----------
    CURRENT ASSETS:
      Cash and cash equivalents                 $64,579,098      $53,843,951
      Accounts receivable, net of allowance
       for doubtful accounts of $1,274,406
       and $1,254,955 as of September 30,
       2010 and December 31, 2009,
       respectively                               6,338,162   1,767,076
      Accounts receivable - related party           247,702          222,617
      Other receivables                           2,678,276        2,186,441
      Inventories, net of allowance for
       obsolete of $653,340 and $519,333 as
       of September 30, 2010 and December
       31, 2009, respectively                    46,584,094       35,132,724
      Prepayments and deferred expense            1,679,041        1,299,125
      Deferred tax assets                         1,285,733        1,053,771
                                                  ---------        ---------
        Total current assets                    123,392,106       95,505,705
                                                -----------       ----------

    PLANT AND EQUIPMENT, net                     36,992,255       28,873,413
                                                 ----------       ----------

    OTHER ASSETS:
      Investment in unconsolidated
       affiliate                                  7,443,372        6,627,355
      Prepayments - non-current                   3,470,787        3,223,960
      Intangible assets, net                     19,198,734       21,180,322
      Goodwill                                   12,425,589       12,425,589
                                                 ----------       ----------
        Total other assets                       42,538,482       43,457,226
                                                 ----------       ----------

           Total assets                        $202,922,843     $167,836,344


                        LIABILITIES AND EQUITY
    ----------------------

    CURRENT LIABILITIES:
      Accounts payable                           $3,787,455       $3,701,843
      Notes payable                                       -           48,598
      Short term loans - bank                     6,062,850        4,474,350
      Short term loans -holder of
       noncontrolling interest                            -        3,652,500
      Other payables and accrued
       liabilities                               22,632,005       19,246,814
      Other payable - related parties             3,150,659        3,087,527
      Accrued interest -holder of
       noncontrolling interest                            -        2,068,526
      Customer deposits                           4,120,667        3,868,577
      Taxes payable                               7,415,225        8,774,079
      Investment payable                             74,816        2,195,365
      Current maturities of notes payable,
       net of discount of $6,639,846 as of
       September 30, 2010                           860,154                -
                                                    -------              ---
        Total current liabilities                48,103,831       51,118,179

    OTHER LIABILITIES:
      Other payable - land use right                329,086          323,687
      Derivative liability -conversion
       option                                    11,255,816       19,960,145
      Fair value of derivative instruments        7,133,071       12,701,262
      Notes payable, net of discount of
       $8,464,380 as of December 31, 2009                 -           89,760
                                                        ---           ------
        Total other liabilities                  18,717,973       33,074,854


           Total liabilities                     66,821,804       84,193,033
                                                 ----------       ----------

    COMMITMENTS AND CONTINGENCIES

    EQUITY:
      Common stock, $0.0001 par value,
       100,000,000 shares authorized,
       23,513,533 and 23,056,442 shares
       issued and outstanding at September
       30 ,2010 and December 31, 2009,
       respectively                                   2,351       2,305
      Additional paid-in-capital                 28,134,566       22,517,077
      Statutory reserves                         26,307,589       17,414,769
      Retained earnings                          33,567,859        5,302,605
      Accumulated other comprehensive
       income                                     5,835,101        4,227,394
                                                  ---------        ---------
        Total shareholders' equity               93,847,466       49,464,150

    NONCONTROLLING INTEREST                      42,253,573       34,179,161
                                                 ----------       ----------

        Total equity                            136,101,039       83,643,311
                                                -----------       ----------

           Total liabilities and equity        $202,922,843     $167,836,344


                  CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES
     CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME (LOSS)
         FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2010 AND 2009
                                   (Unaudited)

                                               Three months ended
                                                 September 30,
                                                      2010           2009
                                                      ----           ----
    REVENUES :
      Revenues                                 $35,847,351    $26,924,616
      Revenues - related party                     156,414        115,123
                                                   -------        -------
        Total revenues                          36,003,765     27,039,739
                                                ----------     ----------

    COST OF REVENUES :
      Cost of revenues                           8,682,502      6,960,901
                                                 ---------      ---------

    GROSS PROFIT                                27,321,263     20,078,838
                                                ----------     ----------

    OPERATING EXPENSES :
      Selling expenses                           2,229,685        619,467
      General and administrative expenses        5,832,118      5,169,137
      Research and development expenses            431,991        262,500
                                                   -------        -------
        Total operating expenses                 8,493,794      6,051,104
                                                 ---------      ---------

    INCOME FROM OPERATIONS                      18,827,469     14,027,734
                                                ----------     ----------

    OTHER (INCOME) EXPENSE :
      Equity in loss (income) of
       unconsolidated affiliate                   (323,015)       (31,051)
      Change in fair value of derivative
       liabilities                              (3,792,793)    13,242,333
      Interest expense, net                        511,287        724,771
      Other income - related party                    (453)             -
      Other expense, net                           142,736        337,645
                                                   -------        -------
        Total other (income) expense , net      (3,462,238)    14,273,698
                                                ----------     ----------

    INCOME BEFORE PROVISION FOR INCOME TAXES
     AND NONCONTROLLING INTEREST                22,289,707       (245,964)

    PROVISION FOR INCOME TAXES                   3,499,558      2,535,023
                                                 ---------      ---------

    NET INCOME (LOSS)                           18,790,149     (2,780,987)

    Less: Net income attributable to
     noncontrolling interest                     5,115,258      3,412,582
                                                 ---------      ---------

    NET INCOME ATTRIBUTABLE TO CONTROLLING
     INTEREST                                   13,674,891     (6,193,569)

    OTHER COMPREHENSIVE INCOME (LOSS) :
      Foreign currency translation adjustments   1,980,488        (61,912)
      Comprehensive (income) loss attributable
       to noncontrolling interest                 (666,131)       (43,287)
                                                  --------        -------
    COMPREHENSIVE INCOME ATTRIBUTABLE TO
     CONTROLLING INTEREST                      $14,989,248    $(6,298,768
                                               ===========    ===========

    BASIC EARNINGS PER SHARE :
      Weighted average number of shares         23,513,533     21,632,793
                                                ==========     ==========
       Earnings per share                            $0.58         $(0.29)
                                                     =====         ======

    DILUTED EARNINGS PER SHARE :
      Weighted average number of shares         26,578,471     21,632,793
                                                ==========     ==========
      Earnings per share                             $0.53         $(0.29)
                                                     =====         ======



                                               Nine months ended
                                                 September 30,
                                                       2010          2009
                                                       ----          ----
    REVENUES :
      Revenues                                 $103,289,680   $80,861,353
      Revenues - related party                      720,954       508,529
                                                    -------       -------
        Total revenues                          104,010,634    81,369,882
                                                -----------    ----------

    COST OF REVENUES :
      Cost of revenues                           26,126,366    22,337,596
                                                 ----------    ----------

    GROSS PROFIT                                 77,884,268    59,032,286
                                                 ----------    ----------

    OPERATING EXPENSES :
      Selling expenses                            5,029,474     2,313,577
      General and administrative expenses        16,700,320    14,996,846
      Research and development expenses           1,332,025     1,098,083
                                                  ---------     ---------
        Total operating expenses                 23,061,819    18,408,506
                                                 ----------    ----------

    INCOME FROM OPERATIONS                       54,822,449    40,623,780
                                                 ----------    ----------

    OTHER (INCOME) EXPENSE :
      Equity in loss (income) of
       unconsolidated affiliate                    (668,670)       19,092
      Change in fair value of derivative
       liabilities                               (9,897,199)   14,931,088
      Interest expense, net                       1,131,345     1,979,538
      Other income - related party                 (915,191)            -
      Other expense, net                            339,970       372,955
                                                    -------       -------
        Total other (income) expense , net      (10,009,745)   17,302,673
                                                -----------    ----------

    INCOME BEFORE PROVISION FOR INCOME TAXES
     AND NONCONTROLLING INTEREST                 64,832,194    23,321,107

    PROVISION FOR INCOME TAXES                   11,782,505     7,547,318
                                                 ----------     ---------

    NET INCOME (LOSS)                            53,049,689    15,773,789

    Less: Net income attributable to
     noncontrolling interest                     15,891,615    10,738,295
                                                 ----------    ----------

    NET INCOME ATTRIBUTABLE TO CONTROLLING
     INTEREST                                    37,158,074     5,035,494

    OTHER COMPREHENSIVE INCOME (LOSS) :
      Foreign currency translation adjustments    2,412,606       349,415
      Comprehensive (income) loss attributable
       to noncontrolling interest                  (804,899)     (437,227)
                                                   --------      --------
    COMPREHENSIVE INCOME ATTRIBUTABLE TO
     CONTROLLING INTEREST                       $38,765,781    $4,947,682
                                                ===========    ==========

    BASIC EARNINGS PER SHARE :
      Weighted average number of shares          23,471,084    21,504,002
                                                 ==========    ==========
       Earnings per share                             $1.58         $0.23
                                                      =====         =====

    DILUTED EARNINGS PER SHARE :
      Weighted average number of shares          26,575,801    21,767,086
                                                 ==========    ==========
      Earnings per share                              $1.44         $0.23
                                                      =====         =====


        CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES
             CONSOLIDATED STATEMENTS OF CASH FLOWS
     FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2010 AND 2009
                          (Unaudited)

                                                    2010           2009
                                                    ----           ----
    CASH FLOWS FROM OPERATING
     ACTIVITIES:
      Net income attributable to
       controlling interest                  $37,158,074     $5,035,494
      Net income attributable to
       noncontrolling interest                15,891,615     10,738,295
                                              ----------     ----------
      Consolidated net income                 53,049,689     15,773,789
      Adjustments to reconcile net income
       to cash provided by operating
       activities:
        Depreciation                           2,379,794      2,158,206
        Amortization                           2,614,637      2,654,269
        Loss on disposal of equipment              9,685        114,246
        Recovery of bad debt previously
         reserved                                 (6,694)        (9,621)
        Allowance for bad debt -accounts
         receivables                                   -         90,442
        Allowance for bad debt -other
         receivables and prepayment              434,105        659,788
        Allowance for obsolete inventories       121,244              -
        Deferred tax assets                     (206,758)             -
        Stock based compensation                 681,653         62,281
        Change in fair value of derivative
         liabilities                          (9,897,199)    14,931,088
        Amortization of deferred note
         issuance cost                           258,753        110,938
        Amortization of discount on
         convertible notes                       784,822         45,175
        Equity in (income) loss of
         unconsolidated affiliate               (668,670)        19,092
      Change in operating assets and
       liabilities:
        Accounts receivable                   (4,450,082)    (1,306,293)
        Accounts receivable -related party       (20,176)       378,308
        Other receivables                       (439,357)      (485,641)
        Inventories                          (10,666,230)    (9,729,616)
        Prepayments and deferred expenses       (746,863)      (511,819)
        Accounts payable                           9,738       (149,764)
        Other payables and accrued
         liabilities                           1,456,220      4,236,622
        Accrued interest -holder of
         noncontrolling interest              (2,068,526)     1,319,555
        Customer deposits                        176,961      4,154,255
        Taxes payable                         (1,510,679)       942,929
                                              ----------        -------
         Net cash provided by operating
          activities                          31,296,067     35,458,229
                                              ----------     ----------

    CASH FLOWS FROM INVESTING
     ACTIVITIES:
      Cash acquired through acquisition                -     11,945,303
      Proceeds from dividend receivable                -        147,256
      Payments made for acquisition           (4,026,415)   (10,373,854)
      Payments made for unconsolidated
       affiliate                                       -     (3,224,980)
      Purchase of plant and equipment         (6,225,041)    (2,323,903)
      Additions to intangible assets             (88,238)    (1,374,146)
      Proceeds from sale of equipment                  -            513
      Advances on non-current assets          (1,249,980)      (855,298)
                                              ----------       --------
         Net cash used in investing
          activities                         (11,589,674)    (6,059,109)
                                             -----------     ----------

    CASH FLOWS FROM FINANCING
     ACTIVITIES:
      Proceeds from warrants conversion          689,160      3,455,059
      Proceeds from issuance of
       convertible notes                               -      8,967,516
      Repayments of former shareholders
       loan in acquiring company                       -     (2,840,914)
      Proceeds from short term loans -
       bank                                    5,884,000     13,515,598
      Payments on short term loans -bank      (4,413,000)    (2,814,528)
      Payments on long term loan - bank                -     (5,863,600)
      Repayments of non-controlling
       shareholder loan                       (3,652,500)             -
      Payments on notes payables                 (48,731)       (29,318)
      Distribution paid to noncontrolling
       interest shareholders                  (8,628,886)    (2,293,888)
                                              ----------     ----------
         Net cash (used in) provided by
          financing activities               (10,169,957)    12,095,925
                                             -----------     ----------

    EFFECTS OF EXCHANGE RATE CHANGE IN
     CASH                                      1,198,711         38,472
                                               ---------         ------

    INCREASE IN CASH                          10,735,147     41,533,517

    CASH and CASH EQUIVALENTS,
     beginning of periods                     53,843,951      8,814,616
                                              ----------      ---------

    CASH and CASH EQUIVALENTS, end of
     periods                                 $64,579,098    $50,348,133
                                             ===========    ===========

    SUPPLEMENTAL DISCLOSURE OF CASH
     FLOW INFORMATION
      Income taxes paid                      $13,477,608     $7,525,262
                                             ===========     ==========
      Interest paid                             $247,649       $911,846
                                                ========       ========
      Non-cash investing and financing
       activities:
        Reclassification of derivative
         liability to equity related to
         conversion of convertible notes      $2,498,957     $5,712,822
                                              ==========     ==========
        Reclassification of derivative
         liability to equity related to
         exercise of warrants                 $1,747,765  $           -
                                              ==========            ===
        Distribution paid in exchange of
         holder of noncontrolling interest
         loan                              $           -     $3,737,283
                                                     ===     ==========
        Distribution paid by offsetting
         accounts receivable -related
         party                             $           -       $943,907
                                                     ===       ========
        Distribution paid by offsetting
         loan due from holder of
         noncontrolling interest           $           -     $4,470,995
                                                     ===     ==========
        Net assets acquired with
         prepayments made in prior periods $           -    $14,248,548
                                                     ===    ===========
        Net assets addition with unpaid
         investment                        $           -     $2,849,710
                                                     ===     ==========
        Plant and equipment addition with
         unpaid commitment                    $1,485,944  $           -
                                              ==========            ===
        Intangible assets acquired with
         prepayments made in prior periods      $441,300       $131,931
                                                ========       ========
        Plant and equipment acquired with
         prepayments made in prior periods      $630,925  $           -
                                                ========            ===



            Company Contact:           Investor Relations Contact:
                                       Mr. Kalle Ahl, CFA, Account
           Mr. Y. Tristan Kuo                    Manager
        Chief Financial Officer          CCG Investor Relations
     China Biologic Products, Inc.       Phone: +1-646-833-3417
         Tel: +86-538-620-2206         Email: kalle.ahl@ccgir.com
      Email: IR@chinabiologic.com           www.ccgirasia.com
         www.chinabiologic.com
                                     Mr. Crocker Coulson, President
                                   Phone: +1-646-213-1915
                                   Email: crocker.coulson@ccgir.com

SOURCE China Biologic Products, Inc.

SOURCE: China Biologic Products, Inc.

China Biologic Products Announces Record Third Quarter 2010 Results - Q3 revenue grew 33.2% to $36.0 million - Non-GAAP adjusted net income grew 48.7% to $10.5 million

PR Newswire

TAI'AN, China, Nov. 16, 2010 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO) ("China Biologic" or the "Company"), one of the leading plasma-based biopharmaceutical companies in the People's Republic of China ("PRC"), operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. ("Shandong Taibang") and Guiyang Dalin Biologic Technologies Co., Ltd. ("Dalin"), and its equity investment in Xi'an Huitian Blood Products Co., Ltd. ("Huitian"), today reported financial results for the third quarter ended September 30, 2010.

Third Quarter 2010 Highlights

  • Revenues increased 33.2% period-over-period to $36.0 million
  • Gross profit rose 36.1% period-over-period to $27.3 million, representing a gross margin of 75.9%, as compared to 74.3% a year ago
  • Income from operations grew 34.2% to $18.8 million
  • GAAP net income attributable to controlling interest was $13.7 million, or $0. 53 per diluted share, including a $3.8 million non-cash gain from change in the fair value of derivative liabilities
  • Excluding the non-cash gain from change in fair value of derivative liabilities, interest on convertible notes and non-cash employee compensation, non-GAAP adjusted net income was $10.5 million or $0.39 per diluted share, a 48.7% increase from $7.1 million, or $0.33 per diluted share a year ago
  • The Company established Ning Yang Taibang Plasma Company and Yi Shui Taibang Plasma Company in July 2010 for the purpose of operating two new plasma stations in Shandong Province, PRC

"Our 2010 third quarter results were very strong, with 33.2% growth in revenues and 48.7% growth in adjusted net income, driven by robust demand and an overall favorable pricing environment for our plasma-based products," said Mr. Chao Ming Zhao, Chief Executive Officer of China Biologic. "During the quarter, we established two new plasma collection stations in Yishui and Ninyang counties in Shandong Province, and we expect to begin trial collections at the Yishui station by the end of the year and at the Ninyang station by early 2011.  We expect that when these sites are at their full capacity, we will realize up to 80 metric tons of incremental plasma collection capacity."

Third Quarter 2010 Results

Revenue for the third quarter of 2010 increased 33.2% to $36.0 million, from $27.0 million in the same period of 2009. Revenue growth was primarily attributable to price increases ranging from 6.2% to 55.8% across the Company's approved product categories, with the exception of human albumin products and human immunoglobulin products, which registered price declines of 4.3% and 11.8%, respectively.  Pricing of human albumin products decreased period-over-period due to higher industry supply primarily from imports. Nonetheless, strong volume growth led to a 51.3% period-over-period increase in human albumin revenue to $17.5 million, or 48.6% of total sales, making it the Company's largest revenue contributor.

Human Immunoglobulin for Intravenous Injection, the Company's second largest revenue contributor at 36.3% of total sales, experienced average period-over-period price increases of 27.0% in third quarter 2010.  Human Hepatitis B Immunoglobulin experienced the sharpest average price increase among the Company's product categories, up 55.8%, compared to the prior year period, and contributed 7.1% of total revenues in third quarter 2010. The average price for human tetanus immunoglobulin products, which contributed 4.1% of total revenues, increased 6.2% period-over-period. The average price for human rabies immunoglobulin products, which contributed 2.9% of total revenues, increased 51.4% period-over-period. The average price for human immunoglobulin products, which contributed 0.5% of total revenues, decreased 11.8%, as compared to the same period in 2009.

Gross profit for the third quarter of 2010 was $27.3 million, up 36.1% from $20.1 million in the third quarter of 2009. Gross profit margin expanded to 75.9%, from 74.3% in the same period a year ago. The gross margin expansion was primarily attributable to increases in the average selling price of four of the Company's six top product categories.

Operating expenses in the third quarter increased 40.4% to $8.5 million, from $6.1 million in the same period last year. Higher expenses primarily reflected a 64.6% increase in research and development spending, mostly related to development of two late stage pipeline products for which the Company expects to receive State Food and Drug Administration ("SFDA") approval in early 2011. Selling expenses increased 259.9% period-over-period to $2.2 million due to intensified promotional and conference activities as the Company continues its efforts in expanding its reach into hospital and inoculation centers. General and administrative expenses increased 12.8% period-over-period in the third quarter of 2010 to $5.8 million, or 16.2% of total sales, versus $5.2 million, or 19.1% of total sales for the same period in 2009.

Income from operations in the 2010 third quarter was $18.8 million, a 34.2% increase from $14.0 million during the same period a year ago. Operating margin rose to 52.3%, from 51.9% in the same period last year.

Total other income was $3.5 million in the 2010 third quarter, as compared to net other expense of $14.3 million in the same period last year. For the three months ended September 30, 2010 and 2009, the Company recognized an income from the change in the fair value of warrant liabilities in the amount of $3.8 million and a loss of $13.2 million, respectively.

Income taxes increased to $3.5 million in the 2010 third quarter, from $2.5 million in the prior year. Net income attributable to controlling interest for the 2010 third quarter was $13.7 million, or $0.53 per diluted share, as compared to $(6.2) million, or $(0.29) per diluted share, during the 2009 third quarter.

Excluding non-cash employee compensation expenses, change in the fair value of derivative liabilities and interest related to the convertible notes under the if-converted method, non-GAAP adjusted net income for the three months ended September 30, 2010 was $10.5 million, or $0.39 per diluted share, up 48.7% from $7.1 million, or $0.33 per diluted share, in the same 2009 period.

Nine Months Results

For the first nine months of 2010, total revenue was $104.0 million, up 27.8% from the first nine months of 2009. Gross profit for the first nine months of 2010 was $77.9 million, up 31.9% from $59.0 million in the comparable period a year ago. Gross margin for the first nine months of 2010 was 74.9%, as compared to 72.5% for the same period in 2009. The increase in gross margin was due mainly to increased selling prices, ranging from 15.1% to 213.6%, across all of the Company's products, except for human albumin products, which decreased by 0.6%. Income from operations for the period was $54.8 million, up 35.0% from $40.6 million in the first nine months of 2009. Net income attributable to controlling interest for the first nine months of 2010 was $37.2 million, up 637.9% from $5.0 million in the first nine months of 2009. Fully diluted earnings per share were $1.44 for the first nine months of 2010, compared to $0.23 in the first nine months of 2009. Excluding non-cash employee compensation expenses, change in the fair value of derivative liabilities and interest related to the convertible notes under the if-converted method, non-GAAP adjusted net income for the nine months ended September 30, 2010 was $28.9 million, or $1.09 per diluted share, an increase of 44.5% from non-GAAP net income of $20.0 million, or $0.92 per fully diluted share, for the nine months ended September 30, 2009.

Financial Condition

As of September 30, 2010, the Company had $64.6 million in cash and cash equivalents, approximately $75.3 million in working capital, and a current ratio of 2.6. Total stockholders' equity at the end of the quarter was $93.8 million, up 89.7% from $49.5 million at the end of 2009.

The Company generated $31.3 million in net cash from operating activities during the first nine months of 2010, as compared to $35.5 million in the same period of 2009, which included a $4.2 million  advanced receipt from customers.

The increase in cash outflow for inventory during the first nine months of 2010, compared to the same period last year, is a direct result of the implementation of the 90-day quarantine period by the PRC government, which caused a longer staging period for its raw material plasma inventory. During the first nine months of 2010, as the Company increased its sales directly to end-users, hospitals and inoculation centers, it also experienced a slower turn-over of its accounts receivable compared to the same period last year.  

Net cash used in investing activities for the nine months ended September 30, 2010 was $11.6 million, as compared to $6.1 million in the same period of 2009. During the first nine months ended September 30, 2010, $1.5 million was used for the acquisition of Ziguang Bio-tech Company, $2.5 million for the final payment for the Dalin acquisition, $1.8 million for equipment for Shandong Taibang, and $5.8 million for the Company's plasma companies' buildings and construction in process in Dalin.

Net cash used in financing activities for the nine months ended September 30, 2010 totaled $10.2 million, as compared to $12.1 million provided by financing activities in the same period of 2009.

Recent Events and Updates

Acquisition of the 17.24% Minority Interest of Taibang Medical

On July 8, 2010, Logic China entered into an equity transfer agreement to purchase 100% of the equity interest in Taibang Medical from the Company's indirect majority-owned subsidiary Shandong Taibang, with a cash purchase price of RMB 6,440,000 (approximately $947,327). The equity transfer was registered with the local Administration for Industry and Commerce ("AIC") on September 10, 2010 and the purchase price was fully paid on September 23, 2010.  With this equity transfer, Taibang Medical is now an indirect wholly-owned subsidiary of the Company and the Company will be able to consolidate its resources in the sales and marketing of Shandong Taibang and Qianfeng's products.

Distributions declaration by Shandong Taibang

On October 9, 2010, the board of directors of Shandong Taibang declared a RMB 70,000,000 (approximately $10,479,000) distribution to its 82.76% shareholder, Logic Express, the Company's wholly-owned subsidiary, and to its 17.24% shareholder, the Shandong Institute. The distribution to Logic Express was used to pay off the RMB 55,000,000 (approximately $8,233,500) loan due to Shandong Taibang, and the distribution to the Shandong Institute was made on October 25, 2010.

Redemption of Convertible Notes

On November 10, 2010, the remaining holder of the Company's convertible notes, issued in the Company's June 2009 financing, exercised its right to convert $2,800,000 payable under its note into an aggregate of 700,000 shares of the Company's common stock.  As a result, only a convertible note in the principal amount of $4,700,000 remains outstanding as of November 16, 2010.

2010 Guidance and Business Outlook

China Biologic reaffirms its guidance for 2010 of revenues in the range of $142 million and $149 million and adjusted net income between $34 million and $36 million. Guidance for 2010 adjusted net income excludes any non-cash gain or loss related to change in the fair value of derivative liabilities, stock-based compensation expense and any adjustments in the U.S. federal income tax provision in 2010 related to the expiration of the look-through exception for Subpart F income on December 31, 2009, and excludes any acquisitions, new product approvals or operational impact from new plasma stations. The guidance also does not assume any material price or volume increases during the year.

Mr. Zhao added, "We believe that the results for the first nine months of 2010 reinforce the merits of China Biologic's strategy to acquire or build new locations, scale up our existing plasma infrastructure, and advance exciting products through our pipeline. From investing in strategic marketing to drive collection center donor volumes, to developing closer relationships with hospitals and inoculation centers, we intend to maximize the utilization of our growing plasma network. We expect that our strong balance sheet and solid operating cash flow will provide us with the resources to take advantage of opportunities created by rising consumer demand and tight supply conditions based on strict government regulation. On the research and development front, we continue to expect our applications for production of Human Prothrombin Complex Conentrate and Human Coagulation Factor VIII to be approved by the SFDA in early 2011. Heading into next year, we intend to leverage our expertise in the field to capitalize further on China's under-pentrated plasma market and build value for our shareholders."

Conference Call

China Biologic will host a conference call at 9:00 a.m. EST on Tuesday, November 16, 2010, to discuss the third quarter 2010 financial results. To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 877-409-5468. International callers should dial +1-702-894-2400. The pass code for the call is 23890623. A replay will be available for 14 days starting on Tuesday, November 16, 2010 at 11:00 a.m. EST. To access the replay, dial 800-642-1687, international callers should dial +1-706-645-9291. The conference pass code is 23890623.

CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES










RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2010, AND 2009











Three Months Ended

Three Months Ended

Nine Months Ended

Nine Months Ended


September 30, 2010

September 30, 2009

September 30, 2010

September 30, 2009


Net Income

Diluted EPS

Net Income

Diluted EPS

Net Income

Diluted EPS

Net Income

Diluted EPS

Adjusted net income - non GAAP

10,489,724

$0.39

7,056,078

$0.33

28,942,653

$1.09

20,028,863

$0.92

Non-cash employee compensation (1)

63,812

$0.00

7,314

$0.00

681,653

$0.03

62,281

$0.00

Loss (income) in fair value of derivative liabilities (2)

(3,792,793)

$(0.14)

13,242,333

$0.61

(9,897,199)

$(0.37)

14,931,088

$0.69

Net income attributable to controlling interest for diluted EPS (3)

14,218,705

$0.53

(6,193,569)

$(0.29)

38,158,199

$1.44

5,034,494

$0.23

Interest add-back on convertible notes

543,814


-


1,000,125


-


Net income attributable to controlling interest

13,674,891


(6,193,569)


37,158,074


5,035,494


Weighted average number of shares - diluted

26,578,471


21,632,793


26,575,801


21,767,086











(1) Non-cash compensation expenses related to options granted to employees and directors under the Company's 2008 Equity Incentive Plan

(2)Adoption of a new accounting rule effective January 1, 2009 requires changes in the fair value of derivative liabilities to be recognized in earnings each quarter.

(3)Net Income attributable to controlling interest for calculating diluted earnings per share includes interest add-back on Convertible Notes.



Use of Non-GAAP Financial Measures

This press release contains non-GAAP financial measures that exclude non-cash compensation expenses related to options granted to employees and directors under the Company's 2008 Equity Incentive Plan and changes in the fair value of derivative liabilities, including warrants and derivative instruments (including the conversion option) embedded in the Company's Senior Secured Convertible Notes. To supplement the Company's condensed consolidated financial statements presented on a GAAP basis, the Company has provided non-GAAP financial information excluding the impact of this item in this release. The Company's management believes that these non-GAAP measures provide investors with a better understanding of how the results relate to the Company's historical performance. A reconciliation of the adjustments to GAAP results appears in the table accompanying this press release. This additional non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP information provided by other companies.

About China Biologic Products, Inc.

China Biologic Products, Inc., through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently one of the leading plasma-based biopharmaceutical companies in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China. Please see the Company's website http://www.chinabiologic.com for additional information.

Safe Harbor Statement

This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiaries. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the ability of the Company to achieve the financial guidance provided by the management; the likelihood that customer demand will continue to rise and the continued ability of the Company to take advantage of opportunities created by such consumer demand and tight supply conditions based on strict government regulation; the ability of the Company to win SFDA approval for its research and development pipeline projects, and commercially launch new products;; the Company's ability to otherwise achieve its commercial objectives, including its ability to continue building new or expanding existing plasma collection stations to increase plasma collection capacity and maximizing the utilization of its growing plasma network, and to gain market share and further strengthen the Company's leadership in the PRC plasma market; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

–FINANCIAL TABLES FOLLOW –

CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
AS OF SEPTEMBER 30, 2010 and DECEMBER 31, 2009


                           ASSETS   




September 30,



December 31,




2010



2009




(Unaudited)





CURRENT ASSETS:







Cash and cash equivalents

$

64,579,098


$

53,843,951


Accounts receivable, net of allowance for doubtful accounts of $1,274,406 and $1,254,955 as of September 30, 2010 and December 31, 2009, respectively


6,338,162



1,767,076


Accounts receivable - related party


247,702



222,617


Other receivables


2,678,276



2,186,441


Inventories, net of allowance for obsolete of $653,340 and $519,333 as of September 30, 2010 and December 31, 2009, respectively


46,584,094



35,132,724


Prepayments and deferred expense


1,679,041



1,299,125


Deferred tax assets


1,285,733



1,053,771


Total current assets


123,392,106



95,505,705









PLANT AND EQUIPMENT, net


36,992,255



28,873,413









OTHER ASSETS:







Investment in unconsolidated affiliate


7,443,372



6,627,355


Prepayments - non-current


3,470,787



3,223,960


Intangible assets, net


19,198,734



21,180,322


Goodwill


12,425,589



12,425,589


Total other assets


42,538,482



43,457,226









Total assets

$

202,922,843


$

167,836,344









                   LIABILITIES AND EQUITY   









CURRENT LIABILITIES:







Accounts payable

$

3,787,455


$

3,701,843


Notes payable


-



48,598


Short term loans - bank


6,062,850



4,474,350


Short term loans - holder of noncontrolling interest


-



3,652,500


Other payables and accrued liabilities


22,632,005



19,246,814


Other payable - related parties


3,150,659



3,087,527


Accrued interest - holder of noncontrolling interest


-



2,068,526


Customer deposits


4,120,667



3,868,577


Taxes payable


7,415,225



8,774,079


Investment payable


74,816



2,195,365


Current maturities of notes payable, net of discount of $6,639,846 as of September 30, 2010


860,154



-


Total current liabilities


48,103,831



51,118,179









OTHER LIABILITIES:







Other payable - land use right


329,086



323,687


Derivative liability - conversion option


11,255,816



19,960,145


Fair value of derivative instruments


7,133,071



12,701,262


Notes payable, net of discount of $8,464,380 as of December 31, 2009


-



89,760


Total other liabilities


18,717,973



33,074,854









Total liabilities


66,821,804



84,193,033









COMMITMENTS AND CONTINGENCIES














EQUITY:







Common stock, $0.0001 par value, 100,000,000 shares authorized, 23,513,533 and 23,056,442 shares issued and outstanding at September 30 ,2010 and December 31, 2009, respectively


2,351



2,305


Additional paid-in-capital


28,134,566



22,517,077


Statutory reserves


26,307,589



17,414,769


Retained earnings


33,567,859



5,302,605


Accumulated other comprehensive income


5,835,101



4,227,394


Total shareholders' equity


93,847,466



49,464,150









NONCONTROLLING INTEREST


42,253,573



34,179,161









Total equity


136,101,039



83,643,311









Total liabilities and equity

$

202,922,843


$

167,836,344





CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME (LOSS)
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2010 AND 2009
(Unaudited)




Three months ended



Nine months ended




September 30,



September 30,




2010



2009



2010



2009


REVENUES :













Revenues

$

35,847,351


$

26,924,616


$

103,289,680


$

80,861,353


Revenues - related party


156,414



115,123



720,954



508,529


Total revenues


36,003,765



27,039,739



104,010,634



81,369,882















COST OF REVENUES :













Cost of revenues


8,682,502



6,960,901



26,126,366



22,337,596















GROSS PROFIT


27,321,263



20,078,838



77,884,268



59,032,286















OPERATING EXPENSES :













Selling expenses


2,229,685



619,467



5,029,474



2,313,577


General and administrative expenses


5,832,118



5,169,137



16,700,320



14,996,846


Research and development expenses


431,991



262,500



1,332,025



1,098,083


Total operating expenses


8,493,794



6,051,104



23,061,819



18,408,506















INCOME FROM OPERATIONS


18,827,469



14,027,734



54,822,449



40,623,780















OTHER (INCOME) EXPENSE :













Equity in loss (income) of unconsolidated affiliate


(323,015)



(31,051)



(668,670)



19,092


Change in fair value of derivative liabilities


(3,792,793)



13,242,333



(9,897,199)



14,931,088


Interest expense, net


511,287



724,771



1,131,345



1,979,538


Other income - related party


(453)



-



(915,191)



-


Other expense, net


142,736



337,645



339,970



372,955


Total other (income) expense , net


(3,462,238)



14,273,698



(10,009,745)



17,302,673















INCOME BEFORE PROVISION FOR INCOME TAXES AND NONCONTROLLING INTEREST


22,289,707



(245,964)



64,832,194



23,321,107















PROVISION FOR INCOME TAXES


3,499,558



2,535,023



11,782,505



7,547,318















NET INCOME (LOSS)


18,790,149



(2,780,987)



53,049,689



15,773,789















Less: Net income attributable to noncontrolling interest


5,115,258



3,412,582



15,891,615



10,738,295















NET INCOME ATTRIBUTABLE TO CONTROLLING INTEREST


13,674,891



(6,193,569)



37,158,074



5,035,494















OTHER COMPREHENSIVE INCOME (LOSS) :













Foreign currency translation adjustments


1,980,488



(61,912)



2,412,606



349,415


Comprehensive (income) loss attributable to noncontrolling interest


(666,131)



(43,287)



(804,899)



(437,227)


COMPREHENSIVE INCOME ATTRIBUTABLE TO CONTROLLING INTEREST

$

14,989,248


$

(6,298,768


$

38,765,781


$

4,947,682















BASIC EARNINGS PER SHARE :













Weighted average number of shares


23,513,533



21,632,793



23,471,084



21,504,002


 Earnings per share

$

0.58


$

(0.29)


$

1.58


$

0.23















DILUTED EARNINGS PER SHARE :













Weighted average number of shares


26,578,471



21,632,793



26,575,801



21,767,086


Earnings per share

$

0.53


$

(0.29)


$

1.44


$

0.23



















CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2010 AND 2009
(Unaudited)




2010



2009


CASH FLOWS FROM OPERATING ACTIVITIES:







Net income attributable to controlling interest

$

37,158,074


$

5,035,494


Net income attributable to noncontrolling interest


15,891,615



10,738,295


Consolidated net income


53,049,689



15,773,789


Adjustments to reconcile net income to cash provided by operating activities:







Depreciation


2,379,794



2,158,206


Amortization


2,614,637



2,654,269


Loss on disposal of equipment


9,685



114,246


Recovery of bad debt previously reserved


(6,694)



(9,621)


Allowance for bad debt - accounts receivables


-



90,442


Allowance for bad debt - other receivables and prepayment


434,105



659,788


Allowance for obsolete inventories


121,244



-


Deferred tax assets


(206,758)



-


Stock based compensation


681,653



62,281


Change in fair value of derivative liabilities


(9,897,199)



14,931,088


Amortization of deferred note issuance cost


258,753



110,938


Amortization of discount on convertible notes


784,822



45,175


Equity in (income) loss of unconsolidated affiliate


(668,670)



19,092


Change in operating assets and liabilities:







Accounts receivable


(4,450,082)



(1,306,293)


Accounts receivable - related party


(20,176)



378,308


Other receivables


(439,357)



(485,641)


Inventories


(10,666,230)



(9,729,616)


Prepayments and deferred expenses


(746,863)



(511,819)


Accounts payable


9,738



(149,764)


Other payables and accrued liabilities


1,456,220



4,236,622


Accrued interest - holder of noncontrolling interest


(2,068,526)



1,319,555


Customer deposits


176,961



4,154,255


Taxes payable


(1,510,679)



942,929


Net cash provided by operating activities


31,296,067



35,458,229









CASH FLOWS FROM INVESTING ACTIVITIES:







Cash acquired through acquisition


-



11,945,303


Proceeds from dividend receivable


-



147,256


Payments made for acquisition


(4,026,415)



(10,373,854)


Payments made for unconsolidated affiliate


-



(3,224,980)


Purchase of plant and equipment


(6,225,041)



(2,323,903)


Additions to intangible assets


(88,238)



(1,374,146)


Proceeds from sale of equipment


-



513


Advances on non-current assets


(1,249,980)



(855,298)


Net cash used in investing activities


(11,589,674)



(6,059,109)









CASH FLOWS FROM FINANCING ACTIVITIES:







Proceeds from warrants conversion


689,160



3,455,059


Proceeds from issuance of convertible notes


-



8,967,516


Repayments of former shareholders loan in acquiring company


-



(2,840,914)


Proceeds from short term loans - bank


5,884,000



13,515,598


Payments on short term loans - bank


(4,413,000)



(2,814,528)


Payments on long term loan - bank


-



(5,863,600)


Repayments of non-controlling shareholder loan


(3,652,500)



-


Payments on notes payables


(48,731)



(29,318)


Distribution paid to noncontrolling interest shareholders


(8,628,886)



(2,293,888)


Net cash (used in) provided by financing activities


(10,169,957)



12,095,925









EFFECTS OF EXCHANGE RATE CHANGE IN CASH


1,198,711



38,472









INCREASE IN CASH


10,735,147



41,533,517









CASH and CASH EQUIVALENTS, beginning of periods


53,843,951



8,814,616









CASH and CASH EQUIVALENTS, end of periods

$

64,579,098


$

50,348,133









SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION







Income taxes paid

$

13,477,608


$

7,525,262


Interest paid

$

247,649


$

911,846


Non-cash investing and financing activities:







Reclassification of derivative liability to equity related to conversion of convertible notes

$

2,498,957


$

5,712,822


Reclassification of derivative liability to equity related to exercise of warrants

$

1,747,765


$

-


Distribution paid in exchange of holder of noncontrolling interest loan

$

-


$

3,737,283


Distribution paid by offsetting accounts receivable - related party

$

-


$

943,907


Distribution paid by offsetting loan due from holder of noncontrolling interest

$

-


$

4,470,995


Net assets acquired with prepayments made in prior periods

$

-


$

14,248,548


Net assets addition with unpaid investment

$

-


$

2,849,710


Plant and equipment addition with unpaid commitment

$

1,485,944


$

-


Intangible assets acquired with prepayments made in prior periods

$

441,300


$

131,931


Plant and equipment acquired with prepayments made in prior periods

$

630,925


$

-












Company Contact:

Investor Relations Contact:              

Mr. Y. Tristan Kuo

Mr. Kalle Ahl, CFA, Account Manager

Chief Financial Officer

CCG Investor Relations

China Biologic Products, Inc.

Phone: +1-646-833-3417

Tel: +86-538-620-2206

Email: kalle.ahl@ccgir.com

Email: IR@chinabiologic.com

www.ccgirasia.com

www.chinabiologic.com



Mr. Crocker Coulson, President


Phone: +1-646-213-1915


Email: crocker.coulson@ccgir.com



SOURCE China Biologic Products, Inc.

CONTACT: Company Contact -- Mr. Y. Tristan Kuo, Chief Financial Officer of China Biologic Products, Inc., +86-538-620-2206, or IR@chinabiologic.com; or Investor Relations Contacts - Mr. Kalle Ahl, CFA, Account Manager of CCG Investor Relations, +1-646-833-3417, or kalle.ahl@ccgir.com, or Mr. Crocker Coulson, President of CCG Investor Relations, +1-646-213-1915, or crocker.coulson@ccgir.com

Web Site: http://www.chinabiologic.com